Potassium Supplements
Drug class: Antineoplastic Agents
Usage of Potassium Supplements
Hypokalemia
Treatment or prevention of hypokalemia (potassium deficiency) in patients in whom dietary measures are inadequate.
Conditions that may indicate or result in potassium deficiency include vomiting, diarrhea, drainage of GI fluids, hyperadrenalism, malnutrition, debilitation, prolonged negative nitrogen balance, prolonged parenteral alimentation without addition of potassium, dialysis, metabolic alkalosis, metabolic or diabetic acidosis, GI tract abnormalities that result in poor absorption, certain renal diseases, and familial periodic paralysis characterized by hypokalemia.
Potassium should be included in long-term electrolyte replacement regimens and has been recommended for routine prophylactic administration following surgery after adequate urine flow has been established.
Potassium replacement may be indicated in patients receiving certain drugs that may sometimes cause potassium depletion (e.g., thiazide diuretics, carbonic anhydrase inhibitors, loop diuretics, some corticosteroids, corticotropin, aminosalicylic acid, amphotericin B). Although ingestion of potassium-rich foods and/or use of potassium-containing salt substitutes may prevent potassium depletion in patients receiving potassium-depleting drugs, judicious prophylactic administration of potassium may be advisable in selected patients during prolonged diuretic or corticosteroid therapy, especially if they are digitalized.
Potassium chloride usually is the salt of choice in the treatment of potassium depletion, since the chloride ion is required to correct hypochloremia which frequently accompanies potassium deficiency and since the citrate, bicarbonate, gluconate, or another alkalinizing salt of potassium may cause hypochloremia, particularly when used in conjunction with chloride-restricted diets.
Alkalinizing potassium salts (acetate, bicarbonate, citrate, gluconate) should be used for treatment of hypokalemia in patients with metabolic acidosis (e.g., renal tubular acidosis).
Potassium also is available as the potassium phosphate salt; however, potassium phosphate usually is used to replace phosphate losses or to correct coexisting hypokalemia and hypophosphatemia.
Hypertension
Inadequate dietary intake of potassium plays an important role in the development of hypertension, and high dietary intake of potassium (including use of potassium supplements) may protect against the development of high blood pressure and improve blood pressure control in patients with hypertension.
Most experts recommend enhanced intake of potassium (3.5–5 g daily) in hypertensive patients as part of lifestyle modifications unless contraindicated by chronic kidney disease (CKD) or use of drugs that reduce potassium excretion. (See Cautions: Precautions and Contraindications.) Increased potassium intake is recommended particularly in those unable to adequately reduce their sodium intake.
Adequate intake of potassium should be considered as a means of preventing the development of hypertension. Food sources high in potassium such as fruits and vegetables are preferred over potassium supplements.
Arrhythmias
Potassium salts may be used cautiously to abolish arrhythmias of cardiac glycoside toxicity precipitated by a loss of potassium.
Elevation of plasma potassium concentrations by 0.5–1.5 mEq/L or to the ULN may be useful in the management of tachyarrhythmias following cardiac surgery, but this strategy should not be used in patients with atrioventricular block since potassium may further impair nodal conduction.
Thallium Toxicity
IV potassium supplements, usually potassium chloride, have been used in the management of thallium poisoning† [off-label] to enhance diuresis and mobilize thallium from tissues; such treatment is limited by the amount of thallium that can be released into the blood without worsening cerebral symptoms.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use Potassium Supplements
Administration
Administer orally or by slow IV infusion. Potassium-containing injections (usually potassium chloride), have been administered by hypodermoclysis† [off-label] (into suBCutaneous tissues).
Potassium acetate, bicarbonate, chloride, citrate, and gluconate can be administered orally. Potassium acetate and chloride can be administered IV.
Whenever possible, potassium supplements should be given orally since the relatively slow absorption from the GI tract prevents sudden, large increases in plasma potassium concentrations. Replace IV potassium therapy with oral supplements and/or ingestion of potassium-rich foods as soon as possible.
Oral Administration
Oral potassium supplements should preferably be administered with or after meals with a full glass of water or fruit juice to minimize the possibility of GI irritation and a saline cathartic effect.
Usually administered orally in 1–4 doses daily. Daily dosage >20 mEq should be divided into several doses and should not be given as a single dose.
Powders or tablets for oral solution should be dissolved and/or diluted and administered according to the manufacturers’ directions.
Extended-release potassium chloride preparations should be reserved for use in patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for those in whom there is a problem of compliance with these latter dosage forms.
IV Infusion
Close monitoring of ECG and plasma potassium concentrations is essential during IV administration of potassium, especially when the rate of administration is >20 mEq/hour. (See Hyperkalemia under Cautions.)
Potassium IV solutions should generally be administered only in patients with adequate urine flow (e.g., administer to postoperative patients only after adequate urine flow established).
In dehydrated patients, 1 liter of potassium-free fluid should be administered prior to initiating potassium therapy.
Local vascular intolerance may limit the ability to administer concentrated solutions; administer via large, high-flow vein (e.g., femoral vein) or administer less concentrated solutions in divided doses via 2 veins simultaneously. Avoid administration of concentrated potassium solutions via subclavian, jugular, or right atrial catheter; local potassium concentrations achieved in the heart may be high and potentially cardiotoxic.
Potassium chloride injection in plastic containers should not be used in series connections with other plastic containers, since such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from the secondary container is complete.
Hyperkalemia has been reported when concentrated potassium chloride solutions were added to IV infusions from a hanging flexible plastic container, apparently as a result of pooling of the concentrated potassium solution at the base of the container and infusion of undiluted solution. Squeezing the container does not facilitate mixing but tends to pump the concentrated solution into the infusion chamber. Such solutions must be carefully mixed by inverting the plastic container during the addition of potassium solutions with subsequent agitation and/or kneading to prevent pooling.
DilutionFor solution and drug compatibility information, see Compatibility under Stability.
Potassium acetate and potassium chloride are available as concentrates that must be diluted prior to IV administration.
Generally, potassium concentrations in IV fluids should not exceed 40 mEq/L. However, higher potassium concentrations (e.g., 60–80 mEq/L) occasionally may be needed initially for management of severe hypokalemia and associated cardiac arrhythmias, diabetic ketoacidosis or diuretic phase of acute renal failure.
Rate of AdministrationMust be administered by slow IV infusion. Generally, rate of administration should not exceed 20 mEq/hour.
More rapid administration occasionally may be necessary for management of severe hypokalemia and associated cardiac arrhythmias or diabetic ketoacidosis or diuretic phase of acute renal failure.
Hypodermoclysis
If administered by hypodermoclysis† [off-label], potassium concentrations should not exceed 10 mEq/L to avoid local pain.
Dosage
Dosage of potassium supplements usually expressed as mEq of potassium.
Normal adult daily potassium requirement and usual dietary intake of potassium is 40–80 mEq; infants may require 2–3 mEq/kg or 40 mEq/m2 daily.
Dosage must be carefully individualized according to the patient’s requirements and response.
To avoid serious hyperkalemia, replacement of potassium deficits must be undertaken gradually, usually over a 3- to 7-day period depending on the severity of the deficit.
Potassium replacement requirements can be estimated only by clinical condition and response, ECG monitoring, and/or plasma potassium determinations.
Dosage Equivalents of Oral Potassium Salts40 mEq of potassium is provided by approximately:
3.9 g of potassium acetate
4.0 g of potassium bicarbonate
3.0 g of potassium chloride
4.3 g of potassium citrate
9.4 g of potassium gluconate
Pediatric Patients
Hypokalemia† [off-label] Prevention or Treatment† [off-label] OralIf used in pediatric patients†, do not exceed 3 mEq/kg daily in young children.
Adults
Hypokalemia Prevention OralAverage dosage approximately 20 mEq daily. Usually should not exceed 200 mEq daily.
Treatment OralUsual dosage is 40–100 mEq or more daily. Usually should not exceed 200 mEq daily.
Prescribing Limits
Pediatric Patients
Hypokalemia† Prevention or Treatment† Oral3 mEq/kg daily for young children.
Adults
Hypokalemia Prevention or Treatment OralUsually should not exceed 200 mEq daily.
Special Populations
Renal Impairment
Cautious dosage selection and careful monitoring recommended in patients with renal impairment.
Geriatric Patients
Select dosage with caution, starting at low end of dosage range, because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.
Warnings
Contraindications
Warnings/Precautions
Warnings
HyperkalemiaHyperkalemia and cardiac arrest can occur following use of potassium supplements in patients with impaired mechanisms for excreting potassium. Most common and serious adverse effect of potassium therapy.
Potentially fatal; can develop rapidly and patients may be asymptomatic. Occurs most frequently with IV potassium (especially if administered too rapidly), but may occur with oral potassium.
Use IV solutions containing potassium with extreme caution, if at all, in patients with hyperkalemia, severe renal failure, or other conditions with potassium retention.
Evaluate renal function before therapy; monitor clinical status with periodic ECGs and/or determinations of plasma potassium concentrations.
Clinical signs and symptoms of hyperkalemia include paresthesia of the extremities, listlessness, mental confusion, weakness or heaviness of the legs, flaccid paralysis, cold skin, gray pallor, peripheral vascular collapse with fall in blood pressure, cardiac arrhythmias, and heart block.
Metabolic AcidosisIn patients who have both hypokalemia and metabolic acidosis, an alkalinizing potassium salt (acetate, bicarbonate, citrate, gluconate) should be used for treatment of hypokalemia.
Fluid Overload and Edematous StatesUse of IV solutions containing potassium may cause fluid and/or solute overload, leading to decreased electrolyte concentrations, overhydration, congestion, and pulmonary edema.
Use IV solutions containing potassium with extreme caution, if at all, in patients with CHF, severe renal insufficiency, or other conditions with sodium retention and edema.
GI LesionsSolid oral dosage forms of potassium have resulted in ulcerative and/or stenotic GI lesion; perforation has occurred. Possibly more frequent with enteric-coated tablets (no longer commercially available in the US).
Administer wax matrix and extended-release preparations with caution; discontinue immediately if abdominal pain, distention, severe vomiting, or GI bleeding occurs.
Reserve use of extended-release potassium chloride preparations for patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for those in whom there is a problem of compliance with these latter dosage forms.
Some experts question the use of any solid potassium preparation, since use of dilute liquid preparations minimizes the risk of GI complications.
Local ReactionsPain and phlebitis may occur at IV administration site, especially with potassium solutions containing ≥30 mEq/L.
General Precautions
Laboratory MonitoringMonitor fluid balance, electrolyte concentrations, and acid-base balance periodically during therapy. Regular serum potassium determinations are recommended, especially in patients with renal impairment or diabetic nephropathy.
Use of Parenteral SolutionsWhen potassium is administered IV in parenteral solutions, consider the cautions, precautions, and contraindications associated with fluid volume and electrolytes contained in the IV infusion fluid.
Specific Populations
PregnancyCategory C.
LactationNot known whether potassium is distributed into milk. Use with caution.
Pediatric UseSafety and efficacy not established.
Geriatric UseResponse in patients ≥65 years of age does not appear to differ from that in younger adults; however, use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.
Monitor renal function.
Renal ImpairmentParenteral solutions containing potassium may cause sodium and/or potassium retention.
Use cautiously; monitor plasma potassium concentrations frequently.
Common Adverse Effects
Hyperkalemia; GI effects (nausea, vomiting, diarrhea, flatulence, abdominal pain or discomfort); infusion site reactions.
What other drugs will affect Potassium Supplements
Specific Drugs
Drug
Interaction
Comments
ACE inhibitors (e.g., Captopril, enalapril)
Increased risk of hyperkalemia
Use concomitantly only if monitored closely; monitor serum potassium frequently
Corticosteroids
Use caution when used concomitantly with parenteral solutions containing potassium
Corticotropin (ACTH)
Use caution when used concomitantly with parenteral solutions containing potassium
Diuretics, potassium-sparing (e.g. amiloride, spironolactone, triamterene)
Increased risk of severe hyperkalemia
Concomitant use contraindicated
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions